Roblox RBLX delivered 19% year-over-year booking growth during the first quarter, meeting the midpoint of management’s ...

Investors look to funds focused on Treasury Inflation-Protected Securities to cushion portfolios against inflation. However, ...

U.S. consumer sentiment is plunging against a backdrop of stubbornly high inflation and slowing economic momentum, a survey showed Friday. The University of Michigan's consumer-confidence survey ...

STOCKHOLM--Getinge shares trade at the bottom of the Stoxx Europe 600 index after the U.S. Food and Drug Administration advised healthcare providers to move away from using the Swedish company's heart ...

CRH backed its guidance for the year as it posted a rise in its main metrics for the first quarter on positive pricing and good weather. The Irish building-materials supplier said Friday that its ...

SYDNEY--QBE Insurance Group confirmed its full-year guidance after premiums grew at the start of the year and with claims tracking to expectations. The insurer on Friday said group gross written ...

E.W. Scripps said revenue rose in the latest quarter, backed by higher political campaign spending, and it has begun a public process to sell its Bounce television network. The Cincinnati, Ohio, ...

Coinbase reported strong first-quarter earnings, as rising cryptocurrency prices and volatility drove higher revenue, which ...

On April 16, the IRS issued Notice 2024-35 in which it announced that the automatic waiver of the excise tax that applies to certain 10-year beneficiaries has been extended to 2024. As a result ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

RAPT Therapeutics shares hit their 52-week low of $4.39 after the company shut down two Phase 2 trials. The stock was trading down 41% at $4.67 on Thursday, and was down 76% in the past 12 months. The ...